H.C. Wainwright Reiterates Buy Rating on Elevation Oncology (ELEV)

March 10, 2025 6:52 AM EDT Send to a Friend
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $6.00 price target on Elevation Oncology (NASDAQ: ELEV).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login